ROS1 and non-small cell lung carcinoma: The aim of the current study was to summarize real-world data in ten academic medical centers (Golnik, Slovenia; Soroka, Israel; Shaare Zedek, Jerusalem, Israel; Meir, Israel; Rambam, Israel; Gdansk, Poland; Warsaw, Poland; Athens, Greece; UHC Zagreb, Croatia; Bnai Zion, Israel) describing testing practices, clinical characteristics and treatment modalities of advanced NSCLC patients with ROS1 rearrangements.